4DMT's Upcoming Investor Conferences and Key Developments

4DMT's Participation in Investor Conferences

4D Molecular Therapeutics, known by its ticker symbol Nasdaq: FDMT, is gearing up to engage with investors at several notable conferences. As a pioneering late-stage biotechnology firm, 4DMT is making significant strides in developing therapeutics that are disease-targeted and durable. These advancements hold promise to redefine treatment methodologies and greatly enhance patient outcomes.

Conference Details

BofA Securities 2025 Healthcare Conference

The first of these events is the BofA Securities 2025 Healthcare Conference, where management is set to participate in discussions about the company’s future and offerings.

Presentation Date: May 14, 2025

Presentation Time: 2:20 p.m. PT

The ability for one-on-one interactions at these conferences signifies the company’s commitment to transparency and investor relations. This is an opportunity for investors to understand more about 4DMT’s innovative work and therapeutic prospects.

RBC Capital Markets 2025 Global Healthcare Conference

Following that, 4DMT will take part in the RBC Capital Markets 2025 Global Healthcare Conference.

Presentation Date: May 21, 2025

Presentation Time: 9:00 a.m. ET

Both conferences will provide platforms for the management team to delve into the company’s transformative therapeutic approaches and answer queries from potential investors.

Webcasts and Archives

For those who cannot attend the live sessions, an archive of the webcasts will be accessible on the 4DMT website for a year, allowing for extended reach and engagement with stakeholders.

Company Profile

4D Molecular Therapeutics is at the forefront of biotechnology, specializing in therapies designed to tackle complex diseases with a focus on long-lasting efficacy. The company’s flagship product, 4D-150, is engineered to treat blinding retinal vascular diseases. It incorporates a unique delivery system for anti-VEGF therapies, allowing a single injection to provide multi-year results, thus significantly reducing the need for frequent treatments.

Currently in Phase 3 development, 4D-150 targets wet age-related macular degeneration and has plans for further applications such as managing diabetic macular edema.

In addition, the company has launched its second candidate, 4D-710, a groundbreaking genetic medicine that facilitates targeted delivery of the CFTR gene to the lungs, showing promise for cystic fibrosis patients. This innovation marks a significant milestone in genetic therapies, showcasing 4DMT’s commitment to bringing novel solutions to complex health challenges.

Regulatory Insights

It's important to note that all product candidates from 4D Molecular Therapeutics remain in various stages of clinical and preclinical evaluation. As a responsible entity, the company emphasizes that these therapies have not yet received approval from the relevant regulatory authorities, including the U.S. FDA. The journey towards approvals is both critical and rigorous, ensuring only the safest and most effective therapies reach the market.

Company Contact Information

For more details, media inquiries can be directed to Jenn Gordon at dna Communications via Media@4DMT.com. For investors, key insights can be obtained from Julian Pei, Head of Investor Relations and Corporate Finance, at Investor.Relations@4DMT.com.

Frequently Asked Questions

1. What are the upcoming investor conferences that 4DMT will attend?

4DMT will participate in the BofA Securities 2025 Healthcare Conference on May 14 and the RBC Capital Markets 2025 Global Healthcare Conference on May 21.

2. What is the focus of 4DMT's therapeutics?

4DMT focuses on developing durable, disease-targeted therapeutics for complex diseases, emphasizing long-lasting treatment outcomes.

3. When will the webcasts of the conferences be available?

The webcasts will be archived on the 4DMT website and available for up to one year for interested stakeholders.

4. What is the status of 4DMT's product candidates?

All current product candidates are either in clinical or preclinical stages, still awaiting regulatory approvals.

5. How can investors stay updated on 4DMT?

Investors can stay updated by visiting the 4DMT website and following their official channels for the latest news and developments.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.